Shahnaz Shahinfar

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint A double-blind, dose-response study of losartan in hypertensive children
    Shahnaz Shahinfar
    Merck Research Laboratories, West Point, Pennsylvania, USA
    Am J Hypertens 18:183-90. 2005
  2. ncbi request reprint A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild t
    Gilbert W Gleim
    Merck Research Laboratories, Merck and Co, Inc, Blue Bell, Pennsylvania, USA
    Clin Ther 28:1639-48. 2006
  3. ncbi request reprint A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension
    Beth Soffer
    Merck and Co, Inc, West Point, Pennsylvania, USA
    Am J Hypertens 16:795-800. 2003
  4. ncbi request reprint Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study
    Andrew M Tershakovec
    Merck Research Laboratories, Merck and Co, Inc, Upper Gwynedd, Pennsylvania, USA
    Diabetes Care 31:445-7. 2008
  5. ncbi request reprint Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
    Zhongxin Zhang
    Merck and Co, Inc, P O Box 4, BL 3 4, West Point, PA 19486, USA
    J Am Soc Nephrol 16:1775-80. 2005
  6. ncbi request reprint Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study
    William F Keane
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Clin J Am Soc Nephrol 1:761-7. 2006
  7. ncbi request reprint The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy
    George W Carides
    Merck and Co Inc, Blue Bell, Pennsylvania 19422, USA
    Pharmacoeconomics 24:549-58. 2006
  8. ncbi request reprint The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study
    William F Keane
    Department of Medicine, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Kidney Int 63:1499-507. 2003
  9. ncbi request reprint Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment
    Tania Z Dickson
    Merck and Co, Inc, P O Box 4, BLX 21, West Point, PA 19486, USA
    J Clin Pharmacol 43:591-603. 2003
  10. ncbi request reprint Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    Wouter B A Eijkelkamp
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
    J Am Soc Nephrol 18:1540-6. 2007

Detail Information

Publications30

  1. ncbi request reprint A double-blind, dose-response study of losartan in hypertensive children
    Shahnaz Shahinfar
    Merck Research Laboratories, West Point, Pennsylvania, USA
    Am J Hypertens 18:183-90. 2005
    ..The aim of this study was to determine the dose-response relationship for losartan, 2.5 to 100 mg, and to assess the safety and tolerability of losartan in hypertensive children 6 to 16 years of age...
  2. ncbi request reprint A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild t
    Gilbert W Gleim
    Merck Research Laboratories, Merck and Co, Inc, Blue Bell, Pennsylvania, USA
    Clin Ther 28:1639-48. 2006
    ..Because patients with hypertension may require >1 antihypertensive agent to control blood pressure (BP), physicians often prescribe a fixed combination of antihypertensive medications...
  3. ncbi request reprint A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension
    Beth Soffer
    Merck and Co, Inc, West Point, Pennsylvania, USA
    Am J Hypertens 16:795-800. 2003
    ..Despite widespread use in hypertensive children, the safety and effectiveness of lisinopril had not been previously tested in a controlled study...
  4. ncbi request reprint Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study
    Andrew M Tershakovec
    Merck Research Laboratories, Merck and Co, Inc, Upper Gwynedd, Pennsylvania, USA
    Diabetes Care 31:445-7. 2008
    ..LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria...
  5. ncbi request reprint Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
    Zhongxin Zhang
    Merck and Co, Inc, P O Box 4, BL 3 4, West Point, PA 19486, USA
    J Am Soc Nephrol 16:1775-80. 2005
    ....
  6. ncbi request reprint Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study
    William F Keane
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Clin J Am Soc Nephrol 1:761-7. 2006
    ..Future trials with a similar patient population and outcomes measures should consider adjusting analyses for baseline risk factors...
  7. ncbi request reprint The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy
    George W Carides
    Merck and Co Inc, Blue Bell, Pennsylvania 19422, USA
    Pharmacoeconomics 24:549-58. 2006
    ..4 years). The objective of this study was to project the effect of losartan compared with placebo on the lifetime incidence of ESRD and associated costs (from a US healthcare system perspective)...
  8. ncbi request reprint The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study
    William F Keane
    Department of Medicine, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis, Minnesota, USA
    Kidney Int 63:1499-507. 2003
    ..We examined the risk factors that predict loss of kidney function (doubling of serum creatinine) or ESRD (dialysis or transplantation) in patients with type 2 diabetes in whom blood pressure was controlled...
  9. ncbi request reprint Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment
    Tania Z Dickson
    Merck and Co, Inc, P O Box 4, BLX 21, West Point, PA 19486, USA
    J Clin Pharmacol 43:591-603. 2003
    ..Overall, the combination of losartan/hydrochlorothiazide was effective in lowering blood pressure and was well tolerated in patients with mild to moderate renal impairment...
  10. ncbi request reprint Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    Wouter B A Eijkelkamp
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
    J Am Soc Nephrol 18:1540-6. 2007
    ..Antihypertensive treatment that is aimed at improving renal outcomes in patients with diabetic nephropathy may therefore require a dual strategy, targeting both SBP and albuminuria reduction...
  11. ncbi request reprint A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension
    Ronald J Hogg
    St Joseph s Hospital and Medical Center, 222 W Thomas Rd, Suite 410, Phoenix, AZ 85013, USA
    Pediatr Nephrol 22:695-701. 2007
    ..h/ml in Groups I and II to 550-570 ng.h/ml in Groups III and IV. No serious adverse events related to lisinopril were reported...
  12. ncbi request reprint Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes
    Wolfgang C Winkelmayer
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA
    Diabetes Care 29:2210-7. 2006
    ....
  13. ncbi request reprint Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies
    Wouter B A Eijkelkamp
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    J Hypertens 25:871-6. 2007
    ....
  14. ncbi request reprint Losartan: lessons learned from the RENAAL study
    Shahnaz Shahinfar
    Merck and Co, Inc, Whitehouse Station, New Jersey, USA
    Expert Opin Pharmacother 7:623-30. 2006
    ..The RENAAL study also provided information that will be valuable to those designing future clinical trials in this patient population. This review highlights key findings from the RENAAL study...
  15. ncbi request reprint Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies
    Albert A Carr
    Circulatory Disease Center, Augusta, Georgia, USA
    Am J Cardiol 96:1530-6. 2005
    ..The beneficial effect of losartan on the reduction of risk for hospitalization for new HF was demonstrated in patients who were at high renal and/or high cardiovascular risk...
  16. ncbi request reprint Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study
    Kiyoshi Kurokawa
    Research Center for Advanced Science and Technology of the University of Tokyo, 4 6 1 Komaba, Meguro ku, Tokyo, 153 8904, Japan, and The Prince of Wales Hospital, Hong Kong, China
    Clin Exp Nephrol 10:193-200. 2006
    ..The original study of 1513 patients included 96 Japanese patients; the present study is a post-hoc analysis of the effects of losartan in this Japanese subpopulation...
  17. ncbi request reprint Losartan and end-organ protection--lessons from the RENAAL study
    Peter R Kowey
    Main Line Health Heart Center, Wynnewood, Philadelphia, USA
    Clin Cardiol 28:136-42. 2005
    ..Diabetic or renally impaired patients are at high cardiovascular risk, a risk potentially increased in patients with both conditions...
  18. ncbi request reprint A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension
    Thomas Wells
    University of Arkansas for Medical Sciences and Arkansas Children s Hospital, Little Rock 72202, USA
    J Clin Pharmacol 42:870-80. 2002
    ..08 mg/kg) administered once daily effectively lowered blood pressure within 2 weeks in most patients. Blood pressure was reduced in a dose-dependent fashion, with larger doses resulting in a greater reduction...
  19. ncbi request reprint Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation
    William H Herman
    Departments of Internal Medicine and Epidemiology, University of Michigan Health System, Ann Arbor, Michigan 48109 0354, USA
    Diabetes Care 26:683-7. 2003
    ..To evaluate the within-trial effect of losartan and conventional antihypertensive therapy (CT) compared with placebo and CT on the economic cost associated with end-stage renal disease (ESRD)...
  20. ncbi request reprint Analysis of metabolic parameters as predictors of risk in the RENAAL study
    Gerald B Appel
    Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Diabetes Care 26:1402-7. 2003
    ....
  21. ncbi request reprint Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis
    Tazeen H Jafar
    Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Ann Intern Med 139:244-52. 2003
    ..Angiotensin-converting enzyme (ACE) inhibitors reduce blood pressure and urine protein excretion and slow the progression of chronic kidney disease...
  22. ncbi request reprint The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis
    Tazeen H Jafar
    New England Medical Center, Tufts University School of Medicine, Boston, MA, USA
    Nephrol Dial Transplant 18:2047-53. 2003
    ..Therefore, we undertook this analysis to explore the independent association of renal disease progression with gender...
  23. ncbi request reprint Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study
    Juliana C N Chan
    Department of Medicine and Therapeutics, The Chinese University Hong Kong, The Prince of Wales Hospital, Hong Kong, Shatin, China
    Diabetes Care 27:874-9. 2004
    ..In this subgroup analysis, we examined the characteristics, response, and adherence to treatment of the Asian population, as well as their baseline predictors of risk of renal end points...
  24. ncbi request reprint Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL
    Dick de Zeeuw
    Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
    Kidney Int 65:2309-20. 2004
    ....
  25. ncbi request reprint The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy
    Wilson Y S Leung
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, N T, Hong Kong, SAR
    Nephrol Dial Transplant 19:2519-25. 2004
    ..In this subgroup analysis from the RENAAL Study, we hypothesized that the intensive care received by patients in a clinical trial setting also reduced the rate of decline in renal function through optimization of all risk factors...
  26. ncbi request reprint Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
    Dick de Zeeuw
    Department of Clinical Pharmacology, Groningen University Medical Center, Ant Deusinglaan 1, 9713 AV Groningen, Netherlands
    Circulation 110:921-7. 2004
    ..Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention...
  27. ncbi request reprint Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy
    Anupama Mohanram
    UT Southwestern Medical Center, Dallas, Texas 75390 8856, USA
    Kidney Int 66:1131-8. 2004
    ..Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD). Anemia is common in diabetics with nephropathy; however, the impact of anemia on progression to ESRD has not been carefully examined...
  28. ncbi request reprint Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results
    Giuseppe Remuzzi
    Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 15:3117-25. 2004
    ..Angiotensin II antagonism is a suitable and well-tolerated treatment for individuals with type 2 diabetes even with GFR levels approaching renal replacement therapy...
  29. pmc ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy
    Hans Henrik Parving
    Department of Medical Endocrinology, Department 2132, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen Ø, Denmark
    J Am Soc Nephrol 19:771-9. 2008
    ..In conclusion, proteinuric type 2 diabetic patients with the D allele of the ACE gene have an unfavorable renal prognosis, which can be mitigated and even improved by losartan...
  30. ncbi request reprint Dialysis delayed is death prevented: a clinical perspective on the RENAAL study
    Merlin C Thomas
    The Baker Medical Research Institute, Victoria, Australia
    Kidney Int 63:1577-9. 2003